Managing cutaneous squamous cell carcinoma (cSCC) is a significant clinical issue, with an average of 1.8 million cases diagnosed per year, and a staggering increase in incidence over the past three decades. |
We present two cases, in which both patients had similar clinical profiles and the same initial Brigham and Women’s Hospital (BWH) and Cancer Staging Manual, 8th Edition (AJCC-8) staging, yet with distinctively different outcomes. |
In a retrospective analysis of the initial biopsies of these patients, the 40-gene expression profile (40-GEP) test demonstrated its ability to distinguish between the biologically less aggressive and biologically more aggressive tumors. |
These cases highlight the utility of the 40-GEP test as an adjunct to enhance cSCC risk stratification, with the potential to improve patient care and outcomes. |
Introduction
Methods
Sample Acquisition and Analysis
Compliance with Ethics Guidelines
Results
Case Presentations
Discussion and Conclusion
Case 1 | Case 2 |
---|---|
65-year-old male | 69-year-old male |
Liver/kidney transplant | Liver transplant |
1.3 cm diameter | 1.5 cm diameter |
Poorly differentiated | Poorly differentiated |
AJCC-8 Stage T1 | AJCC-8 Stage T1 |
BWH Stage T2a | BWH Stage T2a |
40-GEP Class 1 | 40-GEP Class 2B |
Recurrence free | Regional/distant met |